Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TARS Tarsus Pharmaceuticals, Inc.

Closed 11-08 16:00:00 EST

49.42

+2.63

+5.62%

盘后49.42

+0.000.00%

18:38 EST

High49.90	Low46.71	Vol1.04M
Open47.15	D1 Closing46.79	Amplitude6.82%
Mkt Cap1.88B	Tradable Cap1.42B	Total Shares38.04M
T/O50.70M	T/O Rate3.60%	Tradable Shares28.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"TARS","market":"US","secType":"STK","nameCN":"Tarsus Pharmaceuticals, Inc.","latestPrice":49.42,"timestamp":1731099600000,"preClose":46.79,"halted":0,"volume":1037491,"hourTrading":{"tag":"盘后","latestPrice":49.42,"preClose":49.42,"latestTime":"18:38 EST","volume":240610,"amount":11890957.66,"timestamp":1731109125677},"delay":0,"floatShares":28833217,"shares":38041737,"eps":-4.380477,"marketStatus":"Closed","change":2.63,"latestTime":"11-08 16:00:00 EST","open":47.15,"high":49.9,"low":46.71,"amount":50697636.809456006,"amplitude":0.068177,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.380477,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1731315600000},"marketStatusCode":5,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":46.79,"preHourTrading":{"tag":"盘前","latestPrice":47.11,"preClose":46.79,"latestTime":"09:29 EST","volume":195,"amount":9127.55025,"timestamp":1731076199999},"postHourTrading":{"tag":"盘后","latestPrice":49.42,"preClose":49.42,"latestTime":"18:38 EST","volume":240610,"amount":11890957.66,"timestamp":1731109125677},"volumeRatio":0.91023,"impliedVol":1.4306,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/TARS","defaultTab":"news","newsList":[{"id":"2481191857","title":"Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?","url":"https://stock-news.laohu8.com/highlight/detail?id=2481191857","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481191857?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:00","pubTimestamp":1730991612,"startTime":"0","endTime":"0","summary":"The market expects Tarsus Pharmaceuticals, Inc.  to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.This company is expected to post quarterly loss of $0.90 per share in its upcoming report, which represents a year-over-year change of +29.7%.Revenues are expected to be $42.18 million, up 2155.6% ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6Ex_CnpNXcMseRWMhPXBow--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6Ex_CnpNXcMseRWMhPXBow--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tarsus-pharmaceuticals-inc-tars-expected-150012873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TARS"],"gpt_icon":0},{"id":"2481952255","title":"Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481952255","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481952255?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:30","pubTimestamp":1730928600,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., Nov. 06, 2024  -- Tarsus Pharmaceuticals, Inc. , whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 13, 2024 to report its third quarter 2024 financial results and provide a corporate update.Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gMyS26BQhPrGvp8Iqrfh2w--~B/aD0yMTg7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/bf77ea6955a44678487c6e7b6fc866d6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gMyS26BQhPrGvp8Iqrfh2w--~B/aD0yMTg7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/bf77ea6955a44678487c6e7b6fc866d6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tarsus-report-third-quarter-2024-213000822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","TARS"],"gpt_icon":1},{"id":"2481965493","title":"Tarsus Pharmaceuticals Appoints New Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2481965493","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481965493?lang=en_us&edition=fundamental","pubTime":"2024-11-06 05:36","pubTimestamp":1730842565,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Tarsus Pharmaceuticals ( ($TARS) ). Tarsus Pharmaceuticals appointed Elizabeth Yeu, M.D. as Chief Medical Offic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tarsus-pharmaceuticals-appoints-new-chief-medical-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tarsus-pharmaceuticals-appoints-new-chief-medical-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS","BK4007"],"gpt_icon":0},{"id":"2481501363","title":"Tarsus Appoints Elizabeth Yeu, M.d., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2481501363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481501363?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:30","pubTimestamp":1730813401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nTUA6WTN8J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TARS","BK4007"],"gpt_icon":0},{"id":"2481501580","title":"Press Release: Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2481501580","media":"Dow Jones","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481501580?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:30","pubTimestamp":1730813400,"startTime":"0","endTime":"0","summary":"Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company's newly created Medical Organization. IRVINE, Calif., Nov. 05, 2024  -- Tarsus Pharmaceuticals, Inc. , whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024.\"Liz has been an invaluable partner and advisor to Tarsus, and we are thrilled to apply her medical expertise and leadership directly to enhancing the impact of our medical organization as we continue to propel the XDEMVY launch,\" said Dr. Azamian. \"Her unique clinical perspective will be critical to our continued success and leadership in eye care and beyond, as we advance other meaningful pipeline programs addressing areas of significant unmet need.\". Dr. Yeu additionally serves on the Board of Directors of STAAR Surgical, the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4022","TARS","R","BK4007"],"gpt_icon":1},{"id":"2481263939","title":"Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money","url":"https://stock-news.laohu8.com/highlight/detail?id=2481263939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481263939?lang=en_us&edition=fundamental","pubTime":"2024-11-05 19:15","pubTimestamp":1730805339,"startTime":"0","endTime":"0","summary":"Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/heres-why-tarsus-pharmaceuticals-nasdaqtars-can-manage-its-d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","TQQQ","SQQQ","MNQmain","BK4007","QID","LU2210149790.SGD","BK4112","NQmain","EBIT","IE00BKPKM429.USD","IE00BGHQF748.EUR","PSQ","TARS","LU2210150020.SGD",".IXIC","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ","BK4585","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2479990209","title":"Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2479990209","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479990209?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:39","pubTimestamp":1730284740,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc.  shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 20.6% gain over the past four weeks.The sudden soaring of the stock price can be attributed to positive investor expectations regarding the financial performance of Tarsus’ only marketed product in the United States, Xdemvy, approved for demodex blepharitis. The company is also looking to expand the drug’s label to include the treatment of meibomian gland disease. Apart from Xdemvy, the company’s clinical pipeline contains other promising candidates, like TP-04 and TP-05, being developed for papulopustular rosacea and Lyme disease prevention, respectively.For Tarsus Pharmaceuticals, the consensus EPS estimate for the quarter has been revised 1.3% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't u","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WmuVu3t5SDxzgEWpNLnszg--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2a26db43a50c2bdbcbf0b519d7642b3c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WmuVu3t5SDxzgEWpNLnszg--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2a26db43a50c2bdbcbf0b519d7642b3c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tarsus-pharmaceuticals-tars-surges-10-103900611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","TARS","BK4121","SEER"],"gpt_icon":0},{"id":"2479923410","title":"Tarsus Pharmaceuticals rumor highlighted in Betaville blog","url":"https://stock-news.laohu8.com/highlight/detail?id=2479923410","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479923410?lang=en_us&edition=fundamental","pubTime":"2024-10-30 01:15","pubTimestamp":1730222138,"startTime":"0","endTime":"0","summary":"A rumor regarding Tarsus Pharmaceuticals (TARS) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. Published fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-rumor-highlighted-in-betaville-blog?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-rumor-highlighted-in-betaville-blog?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS","BK4007"],"gpt_icon":0},{"id":"2478117994","title":"Barclays Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2478117994","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478117994?lang=en_us&edition=fundamental","pubTime":"2024-10-28 17:06","pubTimestamp":1730106373,"startTime":"0","endTime":"0","summary":"Barclays analyst Balaji Prasad maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-buy-rating-on-tarsus-pharmaceuticals-tars?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-buy-rating-on-tarsus-pharmaceuticals-tars?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS"],"gpt_icon":0},{"id":"2476236754","title":"Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?","url":"https://stock-news.laohu8.com/highlight/detail?id=2476236754","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476236754?lang=en_us&edition=fundamental","pubTime":"2024-10-18 18:41","pubTimestamp":1729248060,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics  shares ended the last trading session 14% higher at $11.97. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.8% loss over the past four weeks.The sudden rise in the stock price was observed after Amicus announced signing a licensing agreement with Teva Pharmaceuticals which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of Amicus' Galafold  123 mg capsules before the related patents expired. The licensing deal grants Teva the right to sell a generic version of Galafold in the United States from Jan. 30, 2037, pending FDA approval.Amicus Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Tarsus Pharmaceuticals, Inc. , another stock in the same industry, closed the last trading session 1.4% lower at $37.07. TARS has returned","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wFaVluoOkcbN5xhPSF35GA--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ea60c5d3630e17d44f311d6ac6395c89","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wFaVluoOkcbN5xhPSF35GA--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ea60c5d3630e17d44f311d6ac6395c89"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amicus-therapeutics-fold-stock-jumps-104100055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065169927.USD","LU2065171402.SGD","LU2065170008.USD","TEVA","FOLD","BK4007","LU2065171311.SGD","TARS","BK4139"],"gpt_icon":0},{"id":"2476129537","title":"Tarsus Pharmaceuticals launches ‘Your Mitey Problem’ TV campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=2476129537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476129537?lang=en_us&edition=fundamental","pubTime":"2024-10-17 20:43","pubTimestamp":1729168993,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals announced the launch of a new direct-to-consumer TV campaign for XDEMVY 0.25%, the first and only FDA approved treatment for...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-launches-your-mitey-problem-tv-campaign?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-launches-your-mitey-problem-tv-campaign?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS","BK4100","BK4007","TV"],"gpt_icon":0},{"id":"2476125578","title":"Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2476125578","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476125578?lang=en_us&edition=fundamental","pubTime":"2024-10-17 20:30","pubTimestamp":1729168200,"startTime":"0","endTime":"0","summary":"Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids Demodex blepharitis is a significant eyelid disease that impacts app","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/17/2964866/0/en/Tarsus-Launches-Your-Mitey-Problem-the-First-Direct-to-Consumer-TV-Campaign-for-XDEMVY-lotilaner-ophthalmic-solution-0-25.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","DB","TV","BK4552","BK4585","BK4100","BK4588","BK4118","TARS","BK4007"],"gpt_icon":0},{"id":"2476064147","title":"Promising Market Potential and Strategic Growth Drive Buy Rating for Tarsus Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2476064147","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476064147?lang=en_us&edition=fundamental","pubTime":"2024-10-17 19:55","pubTimestamp":1729166114,"startTime":"0","endTime":"0","summary":"Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), retaining the price tar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-market-potential-and-strategic-growth-drive-buy-rating-for-tarsus-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-market-potential-and-strategic-growth-drive-buy-rating-for-tarsus-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS"],"gpt_icon":0},{"id":"2474833097","title":"Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2474833097","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474833097?lang=en_us&edition=fundamental","pubTime":"2024-10-10 05:56","pubTimestamp":1728510997,"startTime":"0","endTime":"0","summary":"Net Product Sales: $40.8 million in Q2 2024.Bottles Dispensed: Over 37,000 bottles delivered to patients in Q2 2024.Gross to Net Discount: Improved to 44% in Q2 2024 from 55% in Q1 2024.Operating Expenses: Approximately $74.8 million for Q2 2024.Cash and Marketable Securities: Approximately $323.6 million at the end of Q2 2024.Expected Bottles Dispensed in Q3: Approximately 41,000, a 10% increase over Q2 2024.GuruFocus has detected 5 Warning Signs with TARS.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Tarsus Pharmaceuticals Inc  is expanding its sales force and planning a consumer television campaign to further accelerate growth.The gross to net discount remains relatively high at approximately 44%, which could impact profitability.Operating expenses increased by approximately $9.5 million in Q2 2024, driven by sales and marketing costs and the expanded sales force.A: Bobak Azamian, CEO, anticipates a slight increase in gross-to-ne","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/x1_VfvgnWqG0ZkQt3zIv.Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/032d7ed37797fcc20a347b9bf02a3b4c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/x1_VfvgnWqG0ZkQt3zIv.Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/032d7ed37797fcc20a347b9bf02a3b4c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tarsus-pharmaceuticals-inc-tars-q2-215637912.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TARS"],"gpt_icon":0},{"id":"2474247538","title":"Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Path To Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2474247538","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474247538?lang=en_us&edition=fundamental","pubTime":"2024-10-09 19:25","pubTimestamp":1728473142,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) is possibly approaching a major achievement in its business, so we would...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/tarsus-pharmaceuticals-incs-nasdaqtars-path-to-profitability","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NQmain","PSQ","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4585",".IXIC","IE00B64PRP62.GBP","SQQQ","LU2210149790.SGD","BK4007","IE00BKPKM429.USD","LU2210150020.SGD","MNQmain","QID","IE00B3QW5Z07.USD","TARS","BK4112","QLD","NDAQ","TQQQ"],"gpt_icon":1},{"id":"2470704071","title":"Oppenheimer Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2470704071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470704071?lang=en_us&edition=fundamental","pubTime":"2024-09-27 19:45","pubTimestamp":1727437529,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Francois Brisebois maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-tarsus-pharmaceuticals-tars?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-tarsus-pharmaceuticals-tars?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS","OPY"],"gpt_icon":0},{"id":"2470215002","title":"Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2470215002","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470215002?lang=en_us&edition=fundamental","pubTime":"2024-09-26 05:00","pubTimestamp":1727298000,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., Sept.  25, 2024  (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/25/2953387/0/en/Tarsus-to-Participate-in-Fireside-Chat-at-UBS-Virtual-Ophthalmology-Day-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TARS"],"gpt_icon":0},{"id":"2469529190","title":"Oppenheimer Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2469529190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469529190?lang=en_us&edition=fundamental","pubTime":"2024-09-23 19:45","pubTimestamp":1727091930,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Francois Brisebois maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-tarsus-pharmaceuticals-tars?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-tarsus-pharmaceuticals-tars?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS","OPY"],"gpt_icon":0},{"id":"2469084656","title":"Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations","url":"https://stock-news.laohu8.com/highlight/detail?id=2469084656","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469084656?lang=en_us&edition=fundamental","pubTime":"2024-09-21 03:17","pubTimestamp":1726859854,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc.'s Xdemvy, the first FDA-approved treatment for demodex blepharitis, has shown significant efficacy and rapid revenue growth, with $40.8M revenue in Q2 2024.The company is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 results and ongoing FDA discussions.Strong financials with $323M in cash reserves, a healthy current ratio, and a projected positive cash flow by Q3 2024 support robust growth.A discounted cash flow model estimates a fair value of $52 per share, offering a 56% upside potential, driven by experienced management and conservative market penetration estimates.   Pawel Kacperek Tarsus Pharmaceuticals, Inc.  was founded in 2016 and is based in Irvine, California. The company targets eye diseases with a high unmet need. The problem Blepharitis is a common chronic eye disease that is characterized by","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1488827568/image_1488827568.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1488827568/image_1488827568.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4722381-tarsus-pharmaceuticals-unlocking-growth-potential-with-eye-care-innovations","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["TARS","BK4007"],"gpt_icon":0},{"id":"2463414083","title":"Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2463414083","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463414083?lang=en_us&edition=fundamental","pubTime":"2024-08-29 05:00","pubTimestamp":1724878800,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., Aug.  28, 2024  (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/28/2937407/0/en/Tarsus-to-Participate-in-Fireside-Chat-at-the-2024-Wells-Fargo-Securities-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0683600562.USD","LU0106831901.USD","LU0048573561.USD","LU0072461881.USD","LU2236285917.USD","LU0208291251.USD","TARS","BK4207","LU0320765489.SGD","WFC","LU1791807156.HKD","BK4137","BK4585","BK4504","LU0251131958.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU0256863811.USD","LU0149725797.USD","LU0130517989.USD","LU1280957306.USD","LU1201861249.SGD","IE00B19Z3581.USD","LU1069347547.HKD","LU1035773651.USD","LU0052756011.USD","LU0417517546.SGD","BK4007","LU1074936037.SGD","LU0070302665.USD","LU1267930227.SGD","LU0289960550.SGD","LU0971096721.USD","LU0310800965.SGD","LU0128525689.USD","LU0648001328.SGD","LU0742534661.SGD","LU0787776722.HKD","LU0175139822.USD","LU0251142724.SGD","LU0640476718.USD","BK4501","LU0980610538.SGD","LU1668664300.SGD","BK4588","LU0477156953.USD","LU1363072403.SGD","BK4559","HCSG","LU0130102774.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tarsusrx.com","stockEarnings":[{"period":"1week","weight":0.0517},{"period":"1month","weight":0.3762},{"period":"3month","weight":0.7426},{"period":"6month","weight":0.2646},{"period":"1year","weight":1.8289},{"period":"ytd","weight":1.3106}],"compareEarnings":[{"period":"1week","weight":0.0474},{"period":"1month","weight":0.0392},{"period":"3month","weight":0.1175},{"period":"6month","weight":0.1436},{"period":"1year","weight":0.3622},{"period":"ytd","weight":0.2531}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.056097},{"month":2,"riseRate":0.25,"avgChangeRate":0.056479},{"month":3,"riseRate":0,"avgChangeRate":-0.098569},{"month":4,"riseRate":0.5,"avgChangeRate":0.023334},{"month":5,"riseRate":0.75,"avgChangeRate":0.001731},{"month":6,"riseRate":0.5,"avgChangeRate":-0.041248},{"month":7,"riseRate":0.5,"avgChangeRate":-0.020177},{"month":8,"riseRate":0.75,"avgChangeRate":0.027434},{"month":9,"riseRate":0.75,"avgChangeRate":0.038599},{"month":10,"riseRate":0.75,"avgChangeRate":0.129536},{"month":11,"riseRate":0.6,"avgChangeRate":0.053161},{"month":12,"riseRate":0.5,"avgChangeRate":0.163245}],"exchange":"NASDAQ","name":"Tarsus Pharmaceuticals, Inc.","nameEN":"Tarsus Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tarsus Pharmaceuticals, Inc.(TARS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tarsus Pharmaceuticals, Inc.,TARS,Tarsus Pharmaceuticals, Inc.股票,Tarsus Pharmaceuticals, Inc.股票老虎,Tarsus Pharmaceuticals, Inc.股票老虎国际,Tarsus Pharmaceuticals, Inc.行情,Tarsus Pharmaceuticals, Inc.股票行情,Tarsus Pharmaceuticals, Inc.股价,Tarsus Pharmaceuticals, Inc.股市,Tarsus Pharmaceuticals, Inc.股票价格,Tarsus Pharmaceuticals, Inc.股票交易,Tarsus Pharmaceuticals, Inc.股票购买,Tarsus Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tarsus Pharmaceuticals, Inc.(TARS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction